Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …

Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …

Rapidly progressive dementias (RPDs) are a group of heterogeneous disorders that include
immune-mediated, infectious and metabolic encephalopathies, as well as prion diseases …

Objectives: Identify the risk factors associated with Alzheimer disease. Describe the atypical
presentations of Alzheimer disease. Summarize and differentiate between the preclinical …

Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …

Animal studies suggest that the apolipoprotein E ε4 (APOE ε4) allele is a culprit of early
microglial activation in Alzheimer's disease (AD). Here, we tested the association between …

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases that
affect millions of people worldwide, with both prevalence and incidence increasing with age …

Background The use of blood biomarkers after mild traumatic brain injury (mTBI) has been
widely studied. We have identified eight unresolved issues related to the use of five …